G
Gabriele Arendt
Researcher at University of Düsseldorf
Publications - 123
Citations - 6665
Gabriele Arendt is an academic researcher from University of Düsseldorf. The author has contributed to research in topics: Viral load & Dementia. The author has an hindex of 28, co-authored 122 publications receiving 6108 citations.
Papers
More filters
Journal ArticleDOI
Updated research nosology for HIV-associated neurocognitive disorders
Andrea Antinori,Gabriele Arendt,James T. Becker,Bruce J. Brew,Desiree Byrd,Mariana Cherner,David B. Clifford,Paola Cinque,Leon G. Epstein,K. Goodkin,Magnus Gisslén,Igor Grant,Robert K. Heaton,Jeymohan Joseph,Karen Marder,Camillo Marra,Justin C. McArthur,Michael Nunn,Richard W. Price,Lynn Pulliam,Kevin Robertson,Ned Sacktor,Victor Valcour,Valerie Wojna +23 more
TL;DR: This report reviews the collective experience with HIV-associated neurocognitive disorders (HAND), particularly since the advent of highly active antiretroviral treatment, and their definitional criteria; discusses the impact of comorbidities; and suggests inclusion of the term asymptomatic neuroc cognitive impairment to categorize individuals with subclinical impairment.
Journal ArticleDOI
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases
David B. Clifford,Andrea DeLuca,David M. Simpson,Gabriele Arendt,Gavin Giovannoni,Avindra Nath +5 more
TL;DR: The risk of PML increases with duration of exposure to natalizumab over the first 3 years of treatment as mentioned in this paper and the median treatment duration to onset of symptoms was 25 months (range 6-80 months).
MonographDOI
Leitlinien für Diagnostik und Therapie in der Neurologie
H. C. Diener,C. Weimar,P. Berlit,Günther Deuschl,Christian E. Elger,R. Gold,Werner Hacke,A. Hufschmidt,Heinrich Mattle,U. Meier,W. H. Oertel,H. Reichmann,E. Schmutzhard,Claus-W. Wallesch,M. Weller,Hermann Ackermann,Gabriele Arendt,Ralf Baron,Helmuth Steinmetz,Peter-Dirk Berlit,Christian Bien,F. Birklein,Armin Curt,Marcus Deschauer,Génther Deuschl,Rolf R. Diehl,Hans-Christoph Diener,Marianne Dieterich,Karla Eggert,Christian E. Elger,Matthias Endres,Stefanie Förderreuther,Christian Gerloff,Franz Xaver Glocker,Ralf Gold,Gerhard F. Hamann,Josef Georg Heckmann,Michael G. Hennerici,Wieland Hermann,Stefan Hesse,Dieter Heuß,Wolfgang Jost,Eric Jéttler,Reinhard Kaiser,Hans-Otto Karnath,Oliver Kastrup,Thomas Klockgether,Cornelia Kornblum,Frank Lehmann-Horn,Heinz Reichmann,Frank Leypoldt,Joachim Liepert,Rainer Lindemuth,Albert C. Ludolph,Matthias Maschke,Arne May,Geert Mayer,Hans-Michael Meinck,Uta Meyding-Lamadü,Sandra Verena Méller,Kirsten Méller-Vahl,Roland Nau,Gereon Nelles,W. H. Oertel,Walter Paulus,Hans-Walter Pfister,Marcus Pohl,Mario Prosiegel,Sebastian Rauer,E. Bernd Ringelstein,Felix Rosenow,Carsten Saft,Dirk Sander,Konrad Scheglmann,Uwe Schlegel,Erich Schmutzhard,Christiane Schneider-Gold,Ludger Schöls,Paul W. Schönle,Jörg B. Schulz,Claudia Sommer,Thorsten Steiner,Andreas Straubev,Dominik Straumann,Michael Strupp,Walter Sturm,Martin Tegenthoff,Eckhard Thiel,Angelika Thöne-Otto,Claudia Trenkwalder,Wolfram Ziegler,Roland Veltkamp,Jens Volkmann,Gunnar Wasner,Jörg R. Weber,Christian Weimar,Michael Weller,Heinz Wiendl,Dirk Woitalla,Ullrich Wéllner,Inga Zerr,Josef Zihl +101 more
Journal ArticleDOI
Immune surveillance in multiple sclerosis patients treated with natalizumab
Olaf Stüve,Olaf Stüve,Christina M. Marra,Keith R. Jerome,Keith R. Jerome,Keith R. Jerome,Linda S. Cook,Linda S. Cook,Linda S. Cook,Petra D. Cravens,Sabine Cepok,Elliot M. Frohman,J. Theodore Phillips,Gabriele Arendt,Bernhard Hemmer,Nancy L. Monson,Michael K. Racke +16 more
TL;DR: Whether natalizumab, an antibody against very late activating antigen (VLA)‐4, interferes with central nervous system immune surveillance as assessed by leukocyte cell numbers and cellular phenotypes in cerebrospinal fluid (CSF) and peripheral blood is tested.
Journal ArticleDOI
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
Olaf Stüve,Christina M. Marra,Amit Bar-Or,Masaaki Niino,Petra D. Cravens,Sabine Cepok,Elliot M. Frohman,J. Theodore Phillips,Gabriele Arendt,Keith R. Jerome,Keith R. Jerome,Linda S. Cook,Linda S. Cook,Francois Grand'Maison,Bernhard Hemmer,Nancy L. Monson,Michael K. Racke +16 more
TL;DR: Natalizumab therapy decreased the CSF CD4(+)/CD8(+) ratio of patients with MS to levels similar to those of human immunodeficiency virus-infected patients, which may have implications for the observation that some natalizUMab-treated Patients with MS developed progressive multifocal leukoencephalopathy.